BR0114696A - Uso de antiprogestinas para a indução de apoptose em uma célula - Google Patents
Uso de antiprogestinas para a indução de apoptose em uma célulaInfo
- Publication number
- BR0114696A BR0114696A BR0114696-3A BR0114696A BR0114696A BR 0114696 A BR0114696 A BR 0114696A BR 0114696 A BR0114696 A BR 0114696A BR 0114696 A BR0114696 A BR 0114696A
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- antiprogestins
- antiprogestin
- estra
- acetylphenyl
- Prior art date
Links
- 230000000708 anti-progestin effect Effects 0.000 title abstract 6
- 239000003418 antiprogestin Substances 0.000 title abstract 6
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- -1 4-acetylphenyl Chemical group 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000018199 S phase Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099100P | 2000-10-18 | 2000-10-18 | |
| EP00250342 | 2000-10-18 | ||
| PCT/EP2001/012006 WO2002032432A1 (en) | 2000-10-18 | 2001-10-17 | Use of antiprogestins for the induction of apoptosis in a cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0114696A true BR0114696A (pt) | 2003-11-18 |
Family
ID=26072952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0114696-3A BR0114696A (pt) | 2000-10-18 | 2001-10-17 | Uso de antiprogestinas para a indução de apoptose em uma célula |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1326617B9 (enExample) |
| JP (1) | JP2004511523A (enExample) |
| KR (1) | KR100668024B1 (enExample) |
| CN (1) | CN1209111C (enExample) |
| AT (1) | ATE334683T1 (enExample) |
| AU (2) | AU2361902A (enExample) |
| BG (1) | BG107744A (enExample) |
| BR (1) | BR0114696A (enExample) |
| CA (1) | CA2423020C (enExample) |
| CY (1) | CY1105745T1 (enExample) |
| CZ (1) | CZ299823B6 (enExample) |
| DE (1) | DE60121980T2 (enExample) |
| DK (1) | DK1326617T3 (enExample) |
| EA (1) | EA010593B1 (enExample) |
| EE (1) | EE200300157A (enExample) |
| ES (1) | ES2269492T3 (enExample) |
| HR (1) | HRP20030388A2 (enExample) |
| HU (1) | HUP0301433A3 (enExample) |
| IL (2) | IL154976A0 (enExample) |
| MX (1) | MXPA03002955A (enExample) |
| NO (1) | NO20031741L (enExample) |
| NZ (1) | NZ538347A (enExample) |
| PL (1) | PL360157A1 (enExample) |
| PT (1) | PT1326617E (enExample) |
| SI (1) | SI1326617T1 (enExample) |
| SK (1) | SK4702003A3 (enExample) |
| UA (1) | UA76729C2 (enExample) |
| WO (1) | WO2002032432A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| CA2683517A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases |
| US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| CA2683809A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| AU2012318618B2 (en) * | 2011-10-04 | 2017-01-12 | Invivis Pharmaceuticals Inc. | Methods and systems for identifying and treating anti-progestin sensitive tumors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
-
2001
- 2001-10-17 SK SK470-2003A patent/SK4702003A3/sk not_active Application Discontinuation
- 2001-10-17 DE DE60121980T patent/DE60121980T2/de not_active Expired - Fee Related
- 2001-10-17 AT AT01987669T patent/ATE334683T1/de not_active IP Right Cessation
- 2001-10-17 NZ NZ538347A patent/NZ538347A/en unknown
- 2001-10-17 KR KR1020037005360A patent/KR100668024B1/ko not_active Expired - Fee Related
- 2001-10-17 EP EP01987669A patent/EP1326617B9/en not_active Expired - Lifetime
- 2001-10-17 PT PT01987669T patent/PT1326617E/pt unknown
- 2001-10-17 EA EA200300479A patent/EA010593B1/ru not_active IP Right Cessation
- 2001-10-17 EE EEP200300157A patent/EE200300157A/xx unknown
- 2001-10-17 AU AU2361902A patent/AU2361902A/xx active Pending
- 2001-10-17 MX MXPA03002955A patent/MXPA03002955A/es active IP Right Grant
- 2001-10-17 CA CA002423020A patent/CA2423020C/en not_active Expired - Fee Related
- 2001-10-17 JP JP2002535670A patent/JP2004511523A/ja active Pending
- 2001-10-17 ES ES01987669T patent/ES2269492T3/es not_active Expired - Lifetime
- 2001-10-17 WO PCT/EP2001/012006 patent/WO2002032432A1/en not_active Ceased
- 2001-10-17 HR HR20030388A patent/HRP20030388A2/hr not_active Application Discontinuation
- 2001-10-17 UA UA2003054311A patent/UA76729C2/uk unknown
- 2001-10-17 CN CNB018175694A patent/CN1209111C/zh not_active Expired - Fee Related
- 2001-10-17 AU AU2002223619A patent/AU2002223619B2/en not_active Ceased
- 2001-10-17 BR BR0114696-3A patent/BR0114696A/pt not_active Application Discontinuation
- 2001-10-17 HU HU0301433A patent/HUP0301433A3/hu unknown
- 2001-10-17 SI SI200130648T patent/SI1326617T1/sl unknown
- 2001-10-17 PL PL01360157A patent/PL360157A1/xx not_active Application Discontinuation
- 2001-10-17 CZ CZ20031073A patent/CZ299823B6/cs not_active IP Right Cessation
- 2001-10-17 IL IL15497601A patent/IL154976A0/xx active IP Right Grant
- 2001-10-17 DK DK01987669T patent/DK1326617T3/da active
-
2003
- 2003-03-18 IL IL154976A patent/IL154976A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031741A patent/NO20031741L/no not_active Application Discontinuation
- 2003-04-18 BG BG107744A patent/BG107744A/bg unknown
-
2006
- 2006-11-01 CY CY20061101564T patent/CY1105745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0114665A (pt) | Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio | |
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0113927A (pt) | Processos para retardar a recorrência dos sintomas de herpes vìrus | |
| BR0113447A (pt) | Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| BR0214798A (pt) | Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial | |
| BR0313411A (pt) | Uso de reboxetina para o tratamento de ondas de calor | |
| ECSP034606A (es) | Uso de antiprogestinas para la induccion de apoptosis en una celula | |
| IT1241079B (it) | Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico | |
| BR9908885A (pt) | Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase | |
| CA2423020A1 (en) | Use of antiprogestins for the induction of apoptosis in a cell | |
| NZ504351A (en) | Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen | |
| IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence | |
| UY26965A1 (es) | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| CL2004000579A1 (es) | Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria. | |
| Denham | Prostate cancer: low α/β the only consideration? In regard to Fowler, Chappell, and Ritter: the prospects for new treatments for prostate cancer. IJROBP 2002; 52: 3–5 | |
| BR0010070A (pt) | Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio | |
| TW200733955A (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
| SI1937274T1 (sl) | Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo | |
| ES2113106T3 (es) | Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral. | |
| CO5280075A1 (es) | Drospirenona para terapia de reemplazo de hormonas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |